| Hazard Information | Back Directory | [Uses]
Odronextamab is a stable humanized IgG4 CD20?×?CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research[1]. | [in vivo]
Odronextamab (0.4-1 mg/kg, administered via intraperitoneal injection, single dose) exhibits dose-dependent tumor-suppressive activity in a mouse tumor model[2]. | Animal Model: | Raji cell xenograft tumor mice model[2] | | Dosage: | 0.04, 0.1, 0.4, 1.0 mg/kg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Treatment at doses of 0.4 or 1 mg/kg in mice resulted in complete tumor suppression. In mice receiving 0.04-0.1 mg/kg concentrations of odronextamab, tumor growth was slowed. |
| [References]
[1] Rajat Bannerji, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet H DOI:10.1016/S2352-3026(22)00072-2
[2] Zhu M, et al. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. Clin Transl Sci. 2022 Apr;15(4):954-966. DOI:10.1111/cts.13212 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|